日本乾眼症市場規模、佔有率、趨勢及預測（依疾病類型、藥物類型、產品類型、通路及地區分類），2026-2034年

預計到 2025 年，日本乾眼症市場價值將達到 1.501 億美元，到 2034 年將達到 2.021 億美元，2026 年至 2034 年的複合年成長率為 3.4%。

由於眼表疾病病例持續增加，日本乾眼症問題日益嚴重，因此日本乾眼症市場正經歷顯著成長。日本人口老化速度加快，各年齡層使用電子設備的比例也越來越高。這導致人們對有效解決方案的需求日益成長，從而推動了日本乾眼症市場的發展。眼科研究的進步以及治療方法的改進也促進了日本乾眼症市場佔有率的成長。

主要結論與見解：

• 依疾病類型分類：蒸發性乾眼症在 2025 年佔據市場主導地位，市佔率達 60%。這主要是由於日本老齡人口中瞼板腺功能障礙的高發生率以及長時間接觸電子螢幕，導致淚膜不穩定。
• 按藥物類型分類：潤滑眼藥水將在 2025 年佔據 49% 的市場佔有率，這得益於其廣泛的非處方購買管道、使用方便以及作為治療輕度至中度乾眼症狀的一線療法的既定地位。
• 按產品類型分類，到 2025 年，液體眼藥水將佔 55% 的市場佔有率，這反映出消費者強烈偏好能夠快速起效、即時緩解症狀並適應不同生活方式和治療習慣的配方。
• 按分銷管道分類：到 2025 年，零售藥局將佔據市場主導地位，市場佔有率將達到 46%，這得益於其在日本各地社區藥局網路中提供的便利性和可靠的非處方眼科護理產品。
• 主要參與者：日本乾眼症市場競爭強度適中，成熟的製藥公司和專業的眼科公司競相透過產品創新、配方技術進步和策略聯盟來擴大市場佔有率。

隨著醫療服務提供者、研究人員和患者對乾眼症複雜性的認知不斷加深，並開始關注其治療的各個方面，日本的乾眼症市場也持續發展。 2023年6月，千住製藥株式會社與生物製藥公司Novalic簽署許可協議，共同開發、生產和銷售NOV03（全氟己辛烷眼用溶液），這是一款突破性的無防腐劑乾眼症治療藥物，專為日本市場打造。該藥物是第一個能夠直接抑制乾眼症淚液蒸發的治療方法。日本擁有完善的醫療基礎設施，並採用先進的診斷設備來檢測乾眼症。對無防腐劑配方、創新黏蛋白分泌促進劑和淚液穩定劑的重視，顯示有效的眼科護理方法正在被廣泛採用。數位科技也正在融入傳統的眼科護理中，使患者能夠更方便地獲得個人化的治療方案。有關眼部健康重要性的教育活動也促進了各種乾眼症治療方法的普及。

日本乾眼症市場趨勢：

對不含防腐劑的眼科製劑的需求日益成長

在日本，隨著人們對防腐劑對眼表不良影響（包括角膜上皮損傷和長期使用加重症狀）的認知不斷提高，不含防腐劑的眼藥水的使用量顯著增加。患者和醫護人員都越來越傾向於選擇較溫和的配方來治療慢性乾眼症。藥局和醫院廣泛供應一次性無防腐劑人工淚液和治療性眼藥水，反映了臨床指南的演變和患者偏好的轉變，進一步增強了日本對安全且耐受性良好的眼科製劑的需求。

擴大淚膜導向治療方法的應用

日本在採用淚膜導向的診斷和治療策略方面處於領先地位，該策略著眼於解決乾眼症的根本原因，而不僅僅是緩解症狀。這種方法評估淚膜的破壞模式，並制定個人化的治療方案，以恢復淚液穩定性、房水量和黏蛋白分泌。基於此，淚膜導向診斷（TFOD）和淚膜導向治療（TFOT）的概念最初在日本開發並廣泛應用，能夠根據淚膜動力學和破壞模式對乾眼症亞型進行分類，從而指導更精準、更具針對性的干涉措施。眼科、驗光和生活方式諮詢相結合的多學科診療模式的日益融合，正在推動日本乾眼症市場的成長，並支持針對不同亞型疾病的標靶干預措施的發展。

數位產品引起的眼部疲勞導致的乾眼症正日益受到關注。

在日本，電子設備在職場和日常生活中的廣泛使用導致螢幕相關乾眼症狀急劇增加，尤其是在年輕人和工作年齡層中。長時間使用螢幕會降低眨眼頻率，導致淚液不穩定，並加速乾眼症的發生。例如，日本大規模人口研究報告稱，每天使用影片顯示終端（VDT）超過5小時的人群，其乾眼症盛行率顯著高於每天螢幕使用時間較短的人群，女性患病率約為36.5%，男性約為22.3%。這表明長時間使用電子螢幕與乾眼症狀之間存在關聯。醫療保健專業人員正擴大將數位眼部疲勞評估納入常規眼科檢查，同時進行的宣傳宣傳活動也在推廣預防措施，例如定期休息、調整環境以及使用合適的潤滑劑。

2026-2034年市場展望：

受人口老化、螢幕使用導致的眼睛不適加劇以及淚液管理臨床方法不斷發展的推動，日本乾眼症市場預計將持續成長。各年齡層眼部健康意識提升，以及先進診斷工具和治療方案的普及，正在改善治療環境。政府主導的、旨在促進眼部預防保健的醫療政策，以及患者在慢性病管理中日益增強的參與度，進一步鞏固了該市場的長期成長勢頭。預計到2025年，該市場規模將達到1.501億美元，到2034年將達到2.021億美元，2026年至2034年的複合年成長率（CAGR）為3.4%。

1. 日本乾眼症市場規模有多大？

2. 日本乾眼症市場的預期成長率是多少？

3. 在日本乾眼症市場中，哪一種疾病類型所佔的佔有率最大？

4.推動市場成長的關鍵因素是什麼？

5. 日本乾眼症市場面臨的主要挑戰是什麼？

目錄

第1章：序言

第2章：調查範圍與調查方法

• 調查目標
• 相關利益者
• 數據來源
• 市場估值
• 調查方法

第3章執行摘要

第4章 引言

• 概述
• 主要行業趨勢

第5章：日本乾眼症市場

• 市場概覽
• 市場表現
• 新冠疫情的影響
• 市場預測

第6章 依疾病類型分類的市場區隔

• 蒸發性乾眼症
• 乾眼症

第7章 依藥物類型分類的市場區隔

• 抗發炎藥
• 潤滑眼藥水
• 自體血清眼藥水

第8章 產品市場細分

• 眼藥水
• 凝膠
• 液體擦拭巾
• 眼膏
• 其他

第9章 按分銷管道分類的市場細分

• 醫院藥房
• 零售藥房
• 網路藥房

第10章 按地區分類的市場細分

• 關東地區
• 近畿地區
• 中部地區
• 九州和沖繩地區
• 東北部地區
• 中國地區
• 北海道地區
• 四國地區

第11章 SWOT 分析

• 概述
• 優勢
• 弱點
• 機會
• 威脅

第12章 價值鏈分析

第13章 波特五力分析

• 概述
• 買方的議價能力
• 供應商的議價能力
• 競爭程度
• 新進入者的威脅
• 替代品的威脅

第14章：定價分析

第15章 政策與監管環境

第16章 競爭格局

• 市場結構
• 主要企業
• 主要企業簡介

The Japan dry eye syndrome market size was valued at USD 150.1 Million in 2025 and is projected to reach USD 202.1 Million by 2034, growing at a compound annual growth rate of 3.4% from 2026-2034.

The Japan dry eye syndrome market is witnessing significant growth with the increasing problem of dry eyes in the country due to the ever-increasing cases of ocular surface disorders. The Japanese population is aging at a rapid pace, and the use of digital gadgets is common among all ages. This is fueling the growth of the Japan dry eye syndrome market, with an increase in the need to find the best solutions to this problem. The developments in the study of the eyes and the changing face of the way the problem is being dealt with are all adding to the growth of the Japan dry eye syndrome market share.

KEY TAKEAWAYS AND INSIGHTS:

• By Disease Type: Evaporative dry eye syndrome dominated the market with a share of 60% in 2025 , driven by the high prevalence of meibomian gland dysfunction among Japan's aging population and prolonged digital screen exposure contributing to tear film instability.
• By Drug Type: Lubricant eye drops lead the market with a share of 49% in 2025 , owing to their widespread availability as over-the-counter solutions, ease of use, and established role as the first-line treatment for managing mild to moderate dry eye symptoms.
• By Product: Liquid drops hold the leading market share of 55% in 2025 , reflecting strong consumer preference for convenient, fast-acting formulations that provide immediate symptomatic relief and are compatible with varied lifestyles and treatment routines.
• By Distribution Channel: Retail pharmacies dominate the market with a share of 46% in 2025 , supported by the extensive network of community pharmacies across Japan offering accessible and trusted over-the-counter eye care products.
• Key Players: The Japan dry eye syndrome market features moderate competitive intensity, with established pharmaceutical companies and specialized ophthalmic firms competing through product innovation, formulation advancements, and strategic partnerships to expand their market presence.

The dry eye syndrome market in Japan is moving forward as healthcare providers, researchers, and patients understand the complex nature of the disease and strive to address the various aspects of the condition's management. In June 2023, Senju Pharmaceutical Co., Ltd. entered into a licensing agreement with biopharmaceutical firm Novaliq GmbH to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), a first-in-class, preservative-free treatment that directly targets tear evaporation for dry eye disease in Japan. The country is known to have a well-developed health infrastructure and uses advanced diagnostic tools to detect the disease. Its focus on preservative-free agents, innovative mucin secretagogues, and tear film stabilizers suggests that the country is familiar with methods for effective eye care. Digital technologies are also being integrated into traditional ophthalmological practice, thereby increasing access to individual patient management plans. Awareness campaigns about the importance of eye health have led more people to embrace the various dry eye treatments.

JAPAN DRY EYE SYNDROME MARKET TRENDS:

Rising Demand for Preservative-Free Ophthalmic Formulations

Japan is experiencing a notable shift toward preservative-free eye drops, driven by growing awareness of the adverse effects of preservatives on the ocular surface, including corneal epithelial damage and symptom aggravation during prolonged use. Both patients and clinicians are increasingly favoring gentler formulations for chronic dry eye management. The expanding availability of single-dose preservative-free artificial tears and therapeutic drops across pharmacies and hospitals reflects evolving clinical guidelines and patient preferences, reinforcing the demand for safer, well-tolerated ophthalmic solutions in the country.

Growing Adoption of Tear Film-Oriented Therapeutic Approaches

Japan is at the forefront of adopting tear film-oriented diagnosis and treatment strategies that address the root causes of dry eye rather than merely alleviating symptoms. This approach involves assessing tear film breakup patterns and tailoring therapies to restore tear stability, aqueous volume, and mucin secretion. Building on this paradigm, the concept of tear-film-oriented diagnosis (TFOD) and tear-film-oriented therapy (TFOT), first developed and widely applied in Japan, enables clinicians to classify dry eye subtypes based on tear film dynamics and breakup patterns, guiding more precise, component-targeted interventions. The integration of multi-disciplinary care combining ophthalmology, optometry, and lifestyle guidance is gaining traction, driving Japan dry eye syndrome market growth and encouraging the development of targeted interventions for different subtypes of the condition.

Increasing Focus on Digital Eye Strain-Related Dry Eye

The widespread use of digital devices across workplaces and daily life in Japan is contributing to a surge in screen-related dry eye symptoms, particularly among younger and working-age populations. Extended screen exposure reduces blink frequency and contributes to tear film instability, accelerating dry eye onset. For example, a large population-based study in Japan reported that individuals who used visual display terminals (VDTs) for >=5 hours per day had a significantly higher prevalence of dry eye, with up to around 36.5 % of women and 22.3 % of men affected, compared with those with minimal daily screen time, demonstrating the link between prolonged digital screen use and dry eye symptoms. Healthcare providers are increasingly incorporating digital eye strain assessments into routine eye care, while awareness campaigns are promoting preventive measures such as regular breaks, environmental adjustments, and appropriate lubricant use.

MARKET OUTLOOK 2026-2034:

Japan's dry eye syndrome market is poised for sustained growth, underpinned by the country's aging demographic profile, rising prevalence of screen-related ocular discomfort, and evolving clinical approaches to tear film management. Increasing awareness of eye health across all age groups, combined with expanding access to advanced diagnostic tools and therapeutic options, is strengthening the treatment landscape. Government-led healthcare initiatives promoting preventive eye care, alongside growing patient engagement with chronic disease management, are further reinforcing the long-term growth trajectory of the market. The market generated a revenue of USD 150.1 Million in 2025 and is projected to reach a revenue of USD 202.1 Million by 2034, growing at a compound annual growth rate of 3.4% from 2026-2034.

JAPAN DRY EYE SYNDROME MARKET REPORT SEGMENTATION:

Disease Type Insights:

• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
• The evaporative dry eye syndrome dominates with a market share of 60% of the total Japan dry eye syndrome market in 2025.
• Evaporative dry eye syndrome, mainly associated with meibomian gland dysfunction, is the most common form of this condition in Japan. The leading share indicates the huge impact of environmental factors, screen time elongation, and age-related glandular changes on tear film stability. The aging demographic profile, together with the rapid spread of digital devices at workplaces and educational institutions, hastens the incidence of evaporative dry eye in Japan. The increasing acknowledgement of lipid layer inadequacy as a major cause in disrupting tear film is fueling demand for specific therapeutic interventions.
• Japanese healthcare providers are increasingly focused on targeted treatments that address the root causes of evaporative dry eye, such as warm compress therapies, lipid-based lubricants, and innovative ophthalmic solutions designed to restore tear film integrity. Clinical focus on the identification and management of meibomian gland dysfunction as a root cause is strengthening diagnostic accuracy and treatment effectiveness. Further reinforcement in the dominance of this segment across both hospital and community-based ophthalmology settings is the growing adoption of advanced imaging technologies for gland assessment.

Drug Type Insights:

• Anti-inflammatory Drugs
• Lubricant Eye Drops
• Autologous Serum Eye Drops
• The lubricant eye drops leads with a share of 49% of the total Japan dry eye syndrome market in 2025.
• Lubricating eye drops remain to be the core therapy for the treatment of dry eye conditions within Japan by providing symptomatic relief for patients belonging to all severity categories. The accessibility and easy availability of the eye drops within retail outlets and hospitals, along with their safety profile, appear to be making the therapy the preferred choice for mild and moderate cases of dry eye. Real-world usage data from a large crowdsourced study in Japan showed that among individuals with symptomatic dry eye, artificial tears were the most commonly used type of eye drop (used by 53.4 % of respondents), followed by hyaluronic acid solutions (33.1 %), highlighting the central role of lubricating drops in everyday management.
• The segment remains to benefit from an ongoing improvement in formulation technology to develop hyaluronic acid ingredients and lipid-enriched lubricants. Preservative-free single-dose forms are showing strong market appeal among patients with frequent-use requirements. They are intended to address the issue of long-term ocular surface safety. The over-the-counter format advantage, along with the growing awareness of the need to keep the eyes hydrated, is augmenting the strong market position of eye lubricating drops.

Product Insights:

• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others
• The liquid drops dominates with a market share of 55% of the total Japan dry eye syndrome market in 2025.
• The most widely used dry eye treatment product types in Japan continue to be liquid drops due to the associated ease of administration and quick onset of relief. The dry eye treatment segment includes both prescription and non-prescription products, which range from simple artificial tears to complex therapeutic formulas targeting particular deficiencies in the tear film. The Japanese market favors liquid drop-type dry eye treatment products due to customer familiarity and practicality, as it suits all types of dry eye patients, from mild to severe, with either an active or less active lifestyle.
• The continued development of preservative-free single-dose liquid drop formats is further enhancing their position in the market, addressing consumer concerns related to long-term ocular surface safety. Innovative formulations featuring hyaluronic acids, lipid ingredients, and mucin-stimulating agents are increasing the scope of liquid drop therapy beyond primary hydration. The ease of portable formats, their increasing availability in stores, online pharmacies, as well as consumer awareness of correct usage, is keeping demand for liquid drop formats strong.

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• The retail pharmacies leads with a share of 46% of the total Japan dry eye syndrome market in 2025.
• The primary mode of product distribution for dry eye treatment is through retail pharmacies, which take advantage of the already extensive and well-established infrastructure in Japan. This channel is especially advantageous since it allows patients to access the wide product range available in over-the-counter lubricating eye drops and artificial tears from the numerous retail pharmacies available, which cover the entire country and give patients quick access to such dry eye treatment.
• The level of trust placed in pharmacists to give personalized recommendations on product selection and how to use it correctly contributes to a positive perception for the distribution method. The addition of health consultation services within retail pharmacies contributes to higher consumer engagement in the treatment guidelines set for the self-management of chronic eye conditions. The focus on eye health awareness promotions within retail pharmacies, strategic placement of products within the retail environment, as well as the increasing cooperation between pharmaceutical companies and retail pharmacies, all contribute to the continued market dominance of retail pharmacies.

Regional Insights:

• Kanto Region
• Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• The Kanto Region leads Japan's dry eye syndrome market, driven by its large urban population concentrated in Tokyo and surrounding metropolitan areas. Extensive healthcare infrastructure, high concentration of ophthalmology specialists, and significant prevalence of screen-related ocular strain among office workers are sustaining strong demand for both prescription and over-the-counter dry eye treatments across the region.
• The Kinki Region represents a significant market share, supported by well-established ophthalmology networks and major medical research institutions in Osaka and Kyoto. Growing awareness of dry eye management, expanding availability of advanced therapeutic options, and rising patient engagement with preventive eye care services are strengthening treatment adoption across urban and suburban communities in the region.
• The Central/Chubu Region is experiencing steady growth in dry eye treatment adoption, fueled by expanding healthcare access and rising digital device usage among the working population. Increasing emphasis on preventive eye care services, growing distribution of ophthalmic products through retail pharmacies, and enhanced diagnostic capabilities at regional hospitals are supporting sustained market development.
• The Kyushu-Okinawa Region is contributing to market expansion through improved regional healthcare delivery and growing public awareness of ocular health. Increasing availability of specialized ophthalmic products in retail and hospital pharmacy settings, along with expanding access to ophthalmology consultations in semi-urban areas, is driving broader adoption of dry eye treatments across the region.
• The Tohoku Region is witnessing gradual growth in the dry eye syndrome treatment market, supported by government initiatives to enhance healthcare accessibility in rural and semi-rural areas. Increasing adoption of modern diagnostic tools at regional eye care facilities and expanding community pharmacy networks are improving patient access to effective dry eye management solutions.
• The Chugoku Region is expanding its dry eye care capabilities through improved distribution of ophthalmic products and growing integration of telemedicine in eye health services. Rising patient engagement with preventive ocular health practices and enhanced awareness campaigns in community settings are encouraging broader treatment adoption across the region's urban and rural populations.
• The Hokkaido Region is advancing dry eye treatment awareness through seasonal health campaigns addressing cold and dry climate-related ocular discomfort. Strengthening pharmacy networks, increasing specialist consultations, and growing adoption of lubricant-based therapies during harsh winter months are supporting steady market growth and improving patient outcomes across the territory.
• The Shikoku Region is demonstrating growth potential through enhanced regional healthcare programs and increasing availability of dry eye treatments in community pharmacies. Rising awareness of chronic eye health management, expanding telemedicine services for remote consultations, and growing emphasis on age-related ocular care are collectively supporting gradual market development across the region.

MARKET DYNAMICS:

Growth Drivers:

• Why is the Japan Dry Eye Syndrome Market Growing ?
• Rapidly Aging Population Driving Higher Disease Prevalence
• Japan's demographic landscape, characterized by one of the world's highest proportions of elderly citizens, is a fundamental growth driver for the dry eye syndrome market. Age-related changes in tear gland function, hormonal shifts, and increased prevalence of systemic conditions such as diabetes and autoimmune disorders directly contribute to higher rates of dry eye among older adults. In fact, clinical research in Japan has shown that among individuals aged over 60, definite dry eye was observed in approximately 73.5 % of eyes examined, highlighting the significantly elevated burden of dry eye in an elderly Japanese population. As the elderly population continues to expand, healthcare systems are adapting by integrating routine eye health screenings into geriatric care programs. Ophthalmologists and primary care providers are increasingly emphasizing early detection and proactive management of dry eye as part of comprehensive elder care. This demographic-driven demand is expected to remain a consistent growth catalyst throughout the forecast period.
• Escalating Digital Device Usage Across All Demographics
• The pervasive use of smartphones, computers, tablets, and other digital devices in Japan's highly connected society is significantly contributing to the rising incidence of dry eye symptoms. Prolonged screen exposure reduces blink frequency, disrupts tear film stability, and accelerates evaporative tear loss, leading to increased discomfort and demand for effective treatments. A cross-sectional study of Japanese office workers found that those using visual display terminals (VDTs) for more than 8 hours per day had a significantly higher risk of dry eye disease and exhibited short tear break-up time (<= 5 seconds), a clinical indicator of tear instability, with 78.6 % of participants showing this sign, highlighting the strong association between extended screen use and ocular surface dysfunction in digital work environments. This trend affects not only working-age adults in office environments but also younger populations engaged in extensive digital learning and entertainment activities.
• Advancements in Ophthalmic Treatment Approaches and Formulations
• Continuous innovation in ophthalmic drug development and treatment methodologies is strengthening the therapeutic landscape for dry eye syndrome in Japan. The evolution from basic artificial tear formulations to advanced mucin secretagogues, diquafosol-based therapies, and lipid-stabilizing solutions represents a significant advancement in addressing the multifactorial nature of the condition. Topical rebamipide ophthalmic suspension (Mucosta(R)) is a clinically validated mucin secretagogue that significantly improves tear stability, corneal staining, tear break-up time, and symptoms, highlighting Japan's role in mechanism-targeted therapies. These newer therapeutic approaches target specific pathophysiological mechanisms, offering more effective and tailored relief compared to conventional treatments. The development of novel drug delivery systems, including preservative-free single-dose formats and sustained-release formulations, is improving patient compliance and treatment outcomes.

Market Restraints:

• What Challenges the Japan Dry Eye Syndrome Market is Facing?
• Underdiagnosis and Low Treatment-Seeking Behavior
• Despite the high prevalence of dry eye in Japan, a significant proportion of affected individuals remain undiagnosed or do not actively seek medical treatment. Many patients perceive dry eye symptoms as minor discomforts rather than a medical condition requiring professional intervention. This underdiagnosis limits market penetration and prevents patients from accessing appropriate therapeutic solutions. Cultural tendencies toward self-management and reluctance to visit specialists for perceived minor ailments further contribute to delayed diagnosis and treatment initiation.
• Reimbursement Pressures and Healthcare Cost Containment
• Japan's ongoing healthcare cost containment measures and periodic drug price revisions create pricing pressures for ophthalmic pharmaceutical manufacturers. Regular downward adjustments to National Health Insurance drug prices can reduce revenue potential for prescription dry eye treatments and may discourage investment in newer therapies. These reimbursement constraints can limit the commercial viability of innovative formulations and affect the pace at which advanced therapeutic options become widely available to patients.
• Limited Awareness of Chronic Disease Management Needs
• While awareness of dry eye syndrome is growing, many patients still lack understanding of the chronic and progressive nature of the condition. Inconsistent treatment adherence and premature discontinuation of therapy remain common challenges, particularly among patients who experience temporary symptom relief and assume the condition is resolved. The gap between symptom awareness and understanding of the need for sustained management undermines treatment persistence and reduces the long-term therapeutic impact of available products.

COMPETITIVE LANDSCAPE:

• The Japan dry eye syndrome market is characterized by a moderately competitive environment in which established pharmaceutical companies and specialized ophthalmic firms are actively expanding their product portfolios. Competition is driven by innovation in drug formulations, the development of preservative-free and targeted therapeutic solutions, and the pursuit of regulatory approvals for novel treatment approaches. Companies are investing in clinical research to differentiate their offerings through improved efficacy profiles, enhanced patient convenience, and advanced delivery mechanisms. Strategic collaborations, licensing agreements, and partnerships with international ophthalmic innovators are further intensifying competitive dynamics. The market is also influenced by the growing presence of over-the-counter eye care products, which broadens the competitive landscape beyond prescription pharmaceuticals. As the treatment paradigm evolves, market players are refining their strategies to address unmet clinical needs, strengthen brand recognition among healthcare professionals, and capture greater market share across both hospital and retail pharmacy channels.
• KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the Japan dry eye syndrome market?

2. What is the projected growth rate of the Japan dry eye syndrome market?

3. Which disease type held the largest Japan dry eye syndrome market share?

4. What are the key factors driving market growth?

5. What are the major challenges facing the Japan dry eye syndrome market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Japan Dry Eye Syndrome Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Type

• 6.1 Evaporative Dry Eye Syndrome
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Aqueous Dry Eye Syndrome
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Anti-inflammatory Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Lubricant Eye Drops
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Autologous Serum Eye Drops
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Product

• 8.1 Liquid Drops
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Gel
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Liquid Wipes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Eye Ointment
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Retail Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Online Pharmacies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 Kanto Region
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Kinki Region
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Central/ Chubu Region
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Kyushu-Okinawa Region
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Tohoku Region
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast
• 10.6 Chugoku Region
  • 10.6.1 Market Trends
  • 10.6.2 Market Forecast
• 10.7 Hokkaido Region
  • 10.7.1 Market Trends
  • 10.7.2 Market Forecast
• 10.8 Shikoku Region
  • 10.8.1 Market Trends
  • 10.8.2 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Policy and Regulatory Landscape

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players

List of Figures

• Figure 2: Japan: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020-2025
• Figure 3: Japan: Dry Eye Syndrome Market: Breakup by Disease Type (in %), 2025
• Figure 4: Japan: Dry Eye Syndrome Market: Breakup by Drug Type (in %), 2025
• Figure 5: Japan: Dry Eye Syndrome Market: Breakup by Product (in %), 2025
• Figure 6: Japan: Dry Eye Syndrome Market: Breakup by Distribution Channel (in %), 2025
• Figure 7: Japan: Dry Eye Syndrome Market: Breakup by Region (in %), 2025
• Figure 8: Japan: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 9: Japan: Dry Eye Syndrome (Evaporative) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 10: Japan: Dry Eye Syndrome (Evaporative) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 11: Japan: Dry Eye Syndrome (Aqueous) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 12: Japan: Dry Eye Syndrome (Aqueous) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 13: Japan: Dry Eye Syndrome (Anti-inflammatory Drugs) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 14: Japan: Dry Eye Syndrome (Anti-inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 15: Japan: Dry Eye Syndrome (Lubricant Eye Drops) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 16: Japan: Dry Eye Syndrome (Lubricant Eye Drops) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 17: Japan: Dry Eye Syndrome (Autologous Serum Eye Drops) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 18: Japan: Dry Eye Syndrome (Autologous Serum Eye Drops) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 19: Japan: Dry Eye Syndrome (Liquid Drops) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 20: Japan: Dry Eye Syndrome (Liquid Drops) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 21: Japan: Dry Eye Syndrome (Gel) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 22: Japan: Dry Eye Syndrome (Gel) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 23: Japan: Dry Eye Syndrome (Liquid Wipes) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 24: Japan: Dry Eye Syndrome (Liquid Wipes) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 25: Japan: Dry Eye Syndrome (Eye Ointment) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 26: Japan: Dry Eye Syndrome (Eye Ointment) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 27: Japan: Dry Eye Syndrome (Other Product Types) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 28: Japan: Dry Eye Syndrome (Other Product Types) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 29: Japan: Dry Eye Syndrome (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 30: Japan: Dry Eye Syndrome (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 31: Japan: Dry Eye Syndrome (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 32: Japan: Dry Eye Syndrome (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 33: Japan: Dry Eye Syndrome (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 34: Japan: Dry Eye Syndrome (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 35: Kanto Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 36: Kanto Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 37: Kinki Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 38: Kinki Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 39: Central/ Chubu Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 40: Central/ Chubu Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 41: Kyushu-Okinawa Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 42: Kyushu-Okinawa Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 43: Tohoku Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 44: Tohoku Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 45: Chugoku Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 46: Chugoku Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 47: Hokkaido Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 48: Hokkaido Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 49: Shikoku Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 50: Shikoku Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 51: Japan: Dry Eye Syndrome Industry: SWOT Analysis
• Figure 52: Japan: Dry Eye Syndrome Industry: Value Chain Analysis
• Figure 53: Japan: Dry Eye Syndrome Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Japan: Dry Eye Syndrome Market: Key Industry Highlights, 2025 and 2034
• Table 2: Japan: Dry Eye Syndrome Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
• Table 3: Japan: Dry Eye Syndrome Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
• Table 4: Japan: Dry Eye Syndrome Market Forecast: Breakup by Product (in Million USD), 2026-2034
• Table 5: Japan: Dry Eye Syndrome Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
• Table 6: Japan: Dry Eye Syndrome Market Forecast: Breakup by Region (in Million USD), 2026-2034
• Table 7: Japan: Dry Eye Syndrome Market: Competitive Structure
• Table 8: Japan: Dry Eye Syndrome Market: Key Players